Shots:
- Shionogi announced a planned acquisition of IntraBio for $2.0B, adding AQNEURSA (levacetylleucine) and IntraBio’s rare disease capabilities to its portfolio; the transaction is expected to close between November and December 2026, subject to customary conditions and regulatory approvals
- AQNEURSA is approved in the US and EU for neurological manifestations of Niemann-Pick disease Type C (NPC) and was recently approved by the US FDA for ataxia in adults and pediatric patients with Ataxia-Telangiectasia (A-T), making it the first and only approved treatment for this indication
- The acquisition will provide Shionogi with global rights to AQNEURSA and expand its rare disease capabilities across programs in Pompe disease, Fragile X syndrome, and Jordan’s syndrome, building on its 2026 acquisition of RADICAVA rights
Ref: Shionogi | Image: Shionogi | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information connect with us at connect@pharmashots.com
